Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Copanlisib Dihydrochloride

FDA-approved product (powder, intravenous), marketed as Aliqopa.

Registered studies
10
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Copanlisib Dihydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Follicular lymphoma
  • Neoplasm
  • Neoplasm of mature B-cells

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phosphatidylinositol-3-kinase (pi3k) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli63.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Copanlisib Dihydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Copanlisib Dihydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

    NCT05295589 · start 2022-06-30

    Registered record
    Registry ID
    NCT05295589
    Conditions
    Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
    Interventions
    Computed Tomography; Copanlisib Hydrochloride; Magnetic Resonance Imaging; Olaparib; Paclitaxel; Pegylated Liposomal Doxorubicin Hydrochloride; Topotecan Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-06-30
    Completion
    2023-03-17
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma +8 more
    InterventionComputed Tomography; Copanlisib Hydrochloride; Magnetic Resonance Imaging; Olaparib +3 more
    PhasePhase 2
    Registry statusWithdrawn

  • Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    NCT04939272 · start 2022-06-29

    Registered record
    Registry ID
    NCT04939272
    Conditions
    Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
    Interventions
    Copanlisib Hydrochloride; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-06-29
    Completion
    2027-02-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
    InterventionCopanlisib Hydrochloride; Venetoclax
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

    NCT04345913 · start 2021-03-01

    Registered record
    Registry ID
    NCT04345913
    Conditions
    Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Copanlisib Hydrochloride; Eribulin Mesylate; Magnetic Resonance Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-03-01
    Completion
    2027-05-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Copanlisib Hydrochloride +2 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

    NCT04317105 · start 2020-07-17

    Registered record
    Registry ID
    NCT04317105
    Conditions
    Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Copanlisib Hydrochloride; Echocardiography Test; Ipilimumab; Nivolumab; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2020-07-17
    Completion
    2027-05-06
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Copanlisib Hydrochloride +4 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

    NCT03939897 · start 2020-06-17

    Registered record
    Registry ID
    NCT03939897
    Conditions
    Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Recurrent Breast Carcinoma
    Interventions
    Abemaciclib; Biopsy Procedure; Biospecimen Collection; Copanlisib Hydrochloride; Diagnostic Imaging Testing; Echocardiography Test; Fulvestrant; Multigated Acquisition Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2020-06-17
    Completion
    2027-07-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma +1 more
    InterventionAbemaciclib; Biopsy Procedure; Biospecimen Collection; Copanlisib Hydrochloride +4 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

    NCT03484819 · start 2019-12-13

    Registered record
    Registry ID
    NCT03484819
    Conditions
    Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma
    Interventions
    Copanlisib Hydrochloride; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-12-13
    Completion
    2024-08-14
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma
    InterventionCopanlisib Hydrochloride; Nivolumab
    PhasePhase 2
    Registry statusCompleted

  • Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

    NCT03842228 · start 2019-11-21

    Registered record
    Registry ID
    NCT03842228
    Conditions
    Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Copanlisib Hydrochloride; Durvalumab; Echocardiography Test; Magnetic Resonance Imaging; Olaparib; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2019-11-21
    Completion
    2026-12-31
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Copanlisib Hydrochloride +5 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

    NCT05490771 · start 2018-06-20

    Registered record
    Registry ID
    NCT05490771
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Biopsy Procedure; Computed Tomography; Copanlisib Hydrochloride; Magnetic Resonance Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-06-20
    Completion
    2027-01-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Refractory Lymphoma +2 more
    InterventionBiopsy Procedure; Computed Tomography; Copanlisib Hydrochloride; Magnetic Resonance Imaging
    PhasePhase 2
    Registry statusActive not recruiting

  • Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    NCT03432741 · start 2018-03-27

    Registered record
    Registry ID
    NCT03432741
    Conditions
    Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7
    Interventions
    Belinostat; Carfilzomib; Copanlisib Hydrochloride; Daratumumab; Fludeoxyglucose F-18; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Nivolumab; Obinutuzumab; Pembrolizumab; Positron Emission Tomography; Rituximab; Romidepsin; Saline; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-03-27
    Completion
    2022-10-03
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma +10 more
    InterventionBelinostat; Carfilzomib; Copanlisib Hydrochloride; Daratumumab +11 more
    PhasePhase 1
    Registry statusTerminated

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting